CCA
NVCR icon

Catalyst Capital Advisors’s NovoCure NVCR Stock Holding History

Catalyst Capital Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-34,100
Closed -$5.9M – 357
2020
Q4 		$5.9M Buy
+34,100
New +$4.67M 0.33% 52

Other funds holding NVCR

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Catalyst Capital Advisors's NVCR Position: Q1 2021 in Review

Catalyst Capital Advisors sold out of NovoCure (NVCR) in Q1 2021, closing a stake of 34,100 shares — an estimated $5.9M sold.

Catalyst Capital Advisors first reported a position in NVCR in Q4 2020 and held it in 1 quarter. The position peaked at $5.9M in Q4 2020. 327 funds tracked by Wall St. Rank hold NVCR as of Q1 2021.

  • Catalyst Capital Advisors reported no remaining NovoCure position as of Q1 2021 after selling out during the quarter.
  • Catalyst Capital Advisors sold 34,100 NovoCure shares in Q1 2021, an estimated $5.9M.
  • Catalyst Capital Advisors first reported a position in NovoCure in Q4 2020 and held it in 1 quarter.
  • Catalyst Capital Advisors's NovoCure position peaked at $5.9M in Q4 2020.
  • 327 funds tracked by Wall St. Rank held NovoCure as of Q1 2021.

Based on Catalyst Capital Advisors's 13F filing for Q1 2021, filed 10 May 2021.